Arctigenin suppresses transforming growth factor-beta 1-induced expression of monocyte chemoattractant protein-1 and the subsequent epithelial-mesenchymal transition through reactive oxygen species-dependent ERK/NF-kappa B signaling pathway in renal tubular epithelial cells

作者：Li A^*; Wang J; Zhu D; Zhang X; Pan R; Wang R

来源：Free Radical Research, 2015, 49(9): 1095-1113.

DOI：10.3109/10715762.2015.1038258

• antioxidant capacity
• NADPH oxidase
• redox-sensitive transcription factors
• hydrogen peroxide
• redox signaling

Transforming growth factor-beta 1 (TGF-beta 1) induces expression of the proinflammatory and profibrotic cytokine monocyte chemoattractant protein-1 (MCP-1) in tubular epithelial cells (TECs) and thereby contributes to the tubular epithelial-mesenchymal transition (EMT), which in turn leads to the progression of tubulointerstitial inflammation into tubulointerstitial fibrosis. Exactly how TGF-beta 1 causes MCP-1 over-expression and subsequent EMT is not well understood. Using human tubular epithelial cultures, we found that TGF-beta 1 upregulated the expression of reduced nicotinamide adenine dinucleotide phosphate oxidases 2 and 4 and their regulatory subunits, inducing the production of reactive oxygen species. These reactive species activated a signaling pathway mediated by extracellular signal-regulated kinase (ERK1/2) and nuclear factor-kappa B (NF-kappa B), which upregulated expression of MCP-1. Incubating cultures with TGF-beta 1 was sufficient to induce hallmarks of EMT, such as downregulation of epithelial marker proteins (E-cadherin and zonula occludens-1), induction of mesenchymal marker proteins (alpha-smooth muscle actin, fibronectin, and vimentin), and elevated cell migration and invasion in an EMT-like manner. Overexpressing MCP-1 in cells exposed to TGF-beta 1 exacerbated these EMT-like changes. Pretreating cells with the antioxidant and anti-inflammatory compound arctigenin (ATG) protected them against these TGF-beta 1-induced EMT-like changes; the compound worked by inhibiting the ROS/ERK1/2/NF-kappa B pathway to decrease MCP-1 upregulation. These findings suggest ATG as a new therapeutic candidate to inhibit or even reverse tubular EMT-like changes during progression to tubulointerstitial fibrosis, and they provide the first clues to how ATG may work.

• 出版日期2015
• 单位重庆市中医研究院; 重庆理工大学